Bogdan Mitran is a biomedical engineering researcher at the Department of Medicinal Chemistry; Translational PET Imaging , Uppsala University. His work focuses on molecular imaging using PET/SPECT technologies, particularly for oncological applications including prostate cancer, gliomas, and immune cell dynamics. Current affiliation: Uppsala University Department: Medicinal Chemistry; Translational PET Imaging Expertise: Radiolabeled compound development, preclinical evaluation Research interests center on radiopharmaceutical chemistry , affibody molecule engineering , and chelator optimization to enhance imaging contrast and biodistribution. His recent publications demonstrate innovations in: Non-invasive liver fibrogenesis imaging using RESCA-conjugated affibodies CD69-positive immune cell detection in inflammatory arthritis Dual-targeting PSMA/GRPR heterodimers for prostate cancer theranostics Charge-modified metal-chelator complexes for improved tumor targeting Collaborations span preclinical models , radiochemistry , and multimodal imaging strategies, with active publications in Contrast Media & Molecular Imaging , Scientific Reports , and European Journal of Nuclear Medicine and Molecular Imaging .
Jonas Jögi serves as a Consultant in Clinical Physiology with dual appointments at Lund University's Faculty of Medicine and at Clinical Physiology and Nuclear Medicine in Malmö. His academic profile shows 64 research outputs and active supervision of doctoral research. His institutional affiliation is clearly with Lund University, as evidenced by his university email address (jonas.jogi@med.lu.se) and phone number (+4646173395). Dr. Jögi's research expertise centers on nuclear medicine applications, particularly Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). His work spans renal imaging using novel tracers like [18F]PSMA-1007 and neuroimaging for neurodegenerative conditions including Alzheimer's disease and multiple system atrophy. The research fingerprint associated with his profile shows strong connections to patient medicine (100%), Alzheimer's disease neuroscience (73%), single-photon emission computed tomography (60%), and positron emission tomography neuroscience (45%). Analysis of his recent publication trends reveals a dual focus on advancing imaging techniques for both renal and neurological applications. His work bridges clinical practice with technical innovation, particularly in developing and validating new radiotracers. A significant portion examines PSMA-1007 applications beyond prostate cancer, exploring its potential for renal cortical imaging. In neuroimaging, he contributes to developing tracers for differentiating between neurodegenerative disorders, with notable work on α-synuclein and tau imaging. Dr. Jögi serves as an academic supervisor, currently acting as Assistant Supervisor for Valind, K.'s doctoral dissertation project on "Functional imaging of the renal cortex using 18F-PSMA-1007 PET," which began in March 2021 and remains active. This project has received significant attention, with mentions in 52 news outlets and substantial academic readership. His collaborative network spans multiple institutions internationally, reflecting broad research engagement. Based at Lund University medical facilities in both Lund and Malmö, Dr. Jögi works within departments that provide comprehensive imaging services and research infrastructure. His clinical physiology and nuclear medicine work contributes to United Nations Sustainable Development Goals related to health and well-being, demonstrating the societal impact of his research.
Dr. David Minarik is a Medical Physicist affiliated with the Department of Clinical Physiology and Nuclear Medicine at Lund University, Malmö University Hospital. His research focuses on advanced medical imaging techniques in nuclear medicine and PET/CT applications. Academic affiliation: Lund University Primary department: Clinical Physiology and Nuclear Medicine Research focus: Medical imaging, prostate cancer, radiation dosimetry His research explores: Improving PET/CT image quantification using AI algorithms Comparative analysis of reconstruction methods (OSEM vs. BSREM) Optimizing imaging protocols for prostate cancer staging Evaluating novel gamma camera systems for SPECT-CT applications Investigating absorbed dose calculations in nuclear medicine Comparing PET/MRI with histopathology reference standards Recent publications demonstrate his work's emphasis on clinical implementation of imaging biomarkers, particularly for prostate cancer assessment and renal function evaluation. Current research activities include: Supervising doctoral candidate Karl Valind's work on 18F-PSMA-1007 PET for kidney function Participating in projects developing new imaging biomarkers for prostate cancer prognosis Collaborating on SPECT-CT innovations with Irina Ceric Andelius
Francesco De Cobelli is a Full Professor in Radiotherapy and Diagnostic Imaging at Università Vita-Salute San Raffaele since 2015, serving as Head of Radiology Operating Unit and President of the Nursing Degree Course. His research focuses on interventional radiology, oncology, and cardiovascular imaging, emphasizing AI-driven quantitative imaging biomarkers for treatment response. 1995: Specialization in Radiology, University of Milan 1991: MD, University of Milan 1988: Research Fellowship in Physiology, Case Western Reserve University Research interests span minimally invasive oncological treatments, digital medicine, and AI applications in imaging. His recent publications (2025) highlight advancements in pancreatic cancer staging, hepatocellular carcinoma radioembolization, and thermal ablation efficacy for metastases. PNRR Grant (2022): Liver cancer stratification AIRC Investigator's Grant (2020): Imaging biomarkers World Top 2% Scientist (2022): Stanford University Top 2% Scientist (2019): Mendeley/Scopus He serves on editorial boards of Cancers (MDPI) and Hepatoma Research , and participates in international conferences like ESGAR and ECIO.
Youngho Seo, PhD, is a **Professor** and **Director of Nuclear Imaging Physics** in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF). He also holds a **Professor** position in the Department of Nuclear Engineering at UC Berkeley and serves as a Physicist Faculty Scientist at Lawrence Berkeley National Laboratory. His roles include leading the UCSF Physics Research Laboratory (PRL) and directing the preclinical PET/SPECT/CT/Optical imaging core facility at the UCSF Center for Molecular and Functional Imaging. **Education**: B.S. in Physics (KAIST, 1995) M.S. in Physics (University of Alabama in Huntsville, 1997) M.S. and PhD in Physics (UCLA, 2001–2002), specializing in astroparticle physics Postdoctoral training in neutrino physics (UCLA) and medical imaging physics (UCSF) **Research Focus**: Dr. Seo specializes in **radionuclide/x-ray imaging instrumentation**, **molecular imaging tools (SPECT/CT, PET/CT/MR)**, and **preclinical cancer theranostics**. His work spans small animal imaging, radiopharmaceutical development, and translational applications in oncology and cardiology. **Grants & Awards**: Over 15 NIH grants, including roles as Principal Investigator (PI) or Co-PI for projects like CD46-targeted radioligand therapy and [18F]F-AraG cardiac imaging. Notable awards include the **Alexander R. Margulis Award** (2016) and **Outstanding Teacher Award** (2021–22). **Key Contributions**: Development of **alpha-particle therapies**, **STARPEG nanocarriers**, and **PET imaging biomarkers** for cardiotoxicity. His lab (UCSF PRL) focuses on advancing imaging technologies for clinical translation.
Dr. Enid Eslick is a Senior Lecturer in Clinical Imaging at the University of Sydney's Sydney School of Health Sciences (Discipline of Clinical Imaging) and a Medical Physics Specialist at the Children’s Hospital Westmead Nuclear Medicine Department. She researches population imaging infrastructure, radiopharmaceutical therapies, and clinical trials for cancer and cardiovascular diseases. She is a member of the Charles Perkins Centre and leads projects in advanced imaging techniques. Her work spans quantitative SPECT/CT, lung ventilation imaging, and radionuclide therapy dosimetry, with recent publications on PSMA-targeted therapies and CT validation studies. She supervises PhD students in AI-driven cardiovascular diagnostics and secured an Australian Research Council grant (2011) for linear accelerator development. Research Themes: Cancer theranostics and imaging biomarkers Radiopharmaceutical clinical trial design Cardiovascular imaging innovation
Syed Mohammed Nuruddin is an Associate Professor at the University of Oslo, affiliated with the Department of Pharmacology and Pharmaceutical Biosciences. He leads the Oslo Imaging and Therapy Laboratory (OITL), managing its regulatory compliance and operations. His research focuses on preclinical development of diagnostic PET tracers, radiopharmaceuticals, and advanced imaging techniques for diseases like cancer, neurological disorders, and cardiovascular conditions. Education: PhD in Pharmacology (2014, Norwegian University of Life Sciences), European Master in Animal Breeding and Genetics (2009, Swedish University of Agricultural Sciences), and Doctor of Veterinary Medicine (2004, Shahjalal University of Science & Technology). Research Interests: Nuruddin specializes in PET tracer development, radiopharmaceuticals, and preclinical imaging. His work bridges translational research between academia and industry, with a focus on improving diagnostics and drug discovery through advanced imaging technologies. Publications: His recent work includes studies on MET kinase PET tracers, comparative PET imaging in multiple myeloma, and preclinical evaluations of cabozantinib. These contributions highlight advancements in radiotracer design and theranostic applications. Awards: Recognized with the European Compliance Academy Award for Sterile Production Manager (2014-2017). Collaborations: Engages with institutions like Bayer, Oslo Cyclotron Laboratory, and the Cognitive Health Research group to advance translational research. He promotes OITL's capabilities nationally and internationally. Labs/Teams: Directs the OITL facility, which integrates radiopharmacy, PET-SPECT-CT imaging, and data analysis to support preclinical research and industry partnerships.
Kenneth Matthews serves as the Dr. Charles Smith Distinguished Professor of Medical Physics in the Department of Physics & Astronomy at Louisiana State University's College of Science. He concurrently holds adjunct appointments at LSU's Department of Comparative Biomedical Sciences (as Faculty Manager of the Small Animal Imaging Facility), LSU Health Sciences Center's Department of Radiology, Pennington Biomedical Research Center, and the University of North Texas Health Science Center. His academic background includes: B.A. in Chemistry and Physics from Austin College (1990) Ph.D. in Medical Physics from The University of Chicago (1997) Diplomate certification from the American Board of Radiology (2001) Matthews' research centers on medical imaging physics with emphasis on nuclear medicine applications. His laboratory develops novel imaging systems including X-ray interferometry for lung disease diagnosis (COPD/COVID-19), endorectal digital prostate tomosynthesis (endoDPT), and synchrotron-based techniques. He maintains active interests in radiation protection, shielding design, and radiobiology, particularly regarding Auger electron therapy and radioiodine monitoring. Translational research bridging engineering solutions to clinical applications defines his approach. Analysis of his 2015-2025 publications reveals three dominant research trajectories: (1) Advanced imaging system development (prostate tomosynthesis, X-ray interferometry), (2) Radiation safety protocols (shielding for radiopharmaceuticals, uranium series decay analysis), and (3) Cancer therapy innovations (electromagnetically induced osmotic lysis, VMAT radiotherapy). These works consistently integrate physics principles with clinical oncology and nuclear medicine applications. His scientific recognition includes: Fellow of the American Association of Physicists in Medicine (2017) LSU College of Science Teaching Excellence Award (2018) Southwest AAPM Robert J. Shalek Award (2020) As an educator, Matthews has supervised 19 MS and 3 PhD theses while serving on 57 graduate committees across multiple disciplines. He founded LSU's Physics & Astronomy REU program (2010-2018), mentoring 110 undergraduates. His $10M+ grant portfolio features NIH, NSF, American Cancer Society, and DoD funding for projects including breast cancer interferometry imaging, VMAT radiotherapy optimization, and lung disease diagnostics. Current grants focus on clinical translation of imaging technologies through industry partnerships. He directs the Small Animal Imaging Facility and collaborates with the LIGO-Virgo-KAGRA Collaboration and Hearne Institute of Theoretical Physics, maintaining active roles in the AAPM Southwest Chapter (serving as Treasurer 2020-2024) and RSNA educational initiatives.
Zhen Zhang is a Postdoctoral Associate in Neuroscience at Yale School of Medicine. Their research focuses on developing radiolabeled compounds and molecular imaging agents for cancer diagnosis and therapy. Key areas include FAP-targeted imaging for fibrosis, GRPR-targeted probes for prostate cancer, and CXCR4 antagonists for hematologic malignancies. They have pioneered novel radiopharmaceutical designs using boronic acids, thiazolidine derivatives, and albumin-binding motifs to enhance tumor specificity and reduce off-target effects. Recent work emphasizes PSMA-targeted agents for prostate cancer imaging with improved kidney/salivary gland sparing profiles. Their preclinical studies span theranostic applications in multiple myeloma and melanoma models.
Dr. Zhengxing Zhang is an Associate Research Scientist in the Cardiovascular Research Center at Yale University, affiliated with the Yale School of Medicine. He holds a PhD in Organic Chemistry from Fudan University (2010), followed by postdoctoral training at the University of British Columbia (2012) and BC Cancer (2016). His research focuses on developing radiopharmaceuticals for cardiovascular disease diagnosis, particularly through molecular imaging techniques like PET/SPECT. Education & Training: PhD in Organic Chemistry, Fudan University (2010) Postdoctoral Fellow, University of British Columbia (2012) Postdoctoral Fellow, BC Cancer (2016) Research Interests: Dr. Zhang’s work centers on designing radiolabeled compounds targeting fibroblast activation protein (FAP), gastrin-releasing peptide receptor (GRPR), and collagen turnover markers. His studies aim to enhance diagnostic accuracy for cardiovascular diseases and cancers while minimizing off-target effects. Recent efforts include optimizing radioligand stability, improving tumor-to-kidney contrast ratios, and developing novel theranostic agents. Key Contributions: His recent work includes: Development of SB03178, a FAP-targeted PET tracer Optimization of GRPR-targeted bombesin analogs for prostate cancer imaging Collagen hybridizing peptide-based radiotracers for pulmonary and myocardial fibrosis Laboratories: He is part of the Sadeghi Lab, collaborating on projects involving radiopharmaceutical synthesis and preclinical evaluation.
Dr. Michal Kulon is an Assistant Professor of Radiology & Biomedical Imaging at Yale School of Medicine and Program Director of the Nuclear Radiology Fellowship. He holds an MD from Poznan University of Medical Sciences and a BEngSci in Bioengineering from the University of Pennsylvania. His clinical expertise includes nuclear medicine scans (PET-CT, bone scans, and SPECT-CT) and therapies like radioactive iodine and Lutathera. His research focuses on informatics, natural language processing, machine vision, and applying deep learning to medical imaging challenges such as denoising PET images for obese patients and enhancing high-count PET image generation. Dr. Kulon has collaborated with researchers like Anne Marie Boustani and Chi Liu on projects addressing imaging biomarkers, vaccine effects, and oncologic imaging. His work spans clinical and translational research, including studies on inferior vena cava syndrome in prostate cancer and the utility of Lipiodol in liver cancer treatment. As a sub-investigator in the Cognitive Training Study for Parkinson’s Disease, he contributes to advancing neuroimaging applications. Dr. Kulon’s academic contributions bridge cutting-edge AI techniques with clinical radiology, aiming to improve diagnostic accuracy and patient care.
Dr. Sandra T. van Tiel is a Researcher affiliated with Erasmus MC (Erasmus University Medical Center), part of Erasmus University Rotterdam. She completed her doctoral thesis in 2020 on cellular imaging applications in regenerative medicine, cancer, and osteoarthritis. Her research focuses on pharmacology, oncology, and medical imaging, with expertise in macrophage biology, inflammation, and radiotracer development for diagnostic and therapeutic purposes. Key research areas include the development of novel radiotracers targeting somatostatin receptors and GRPR antagonists for imaging applications in cancer and inflammatory diseases. Her work bridges translational research, with contributions to pre-clinical studies on macrophage phenotypes in musculoskeletal disorders and prostate cancer imaging. Her publications demonstrate interdisciplinary collaboration across pharmacology, radiology, and orthopaedic research. While no formal awards are listed, her work has been cited and utilized in patents, reflecting impactful contributions to biomedical imaging and oncology.
Chiti Arturo is a Full Professor in the Department of Imaging and Radiotherapy at the School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. He serves as a doctoral advisor in the Molecular and Experimental Medicine program at Humanitas University for cycles 31-38 (2015-2022) and teaches Master's-level courses in Health Informatics ("Images in healthcare - radiomics") and undergraduate Radiobiology. His research spans critical areas of: Nuclear Medicine Radiology Oncology Molecular Imaging Radiotherapy Medical Imaging Recent publications reveal a pronounced focus on PET imaging innovations for cancer management, including motion correction in pediatric brain tumor studies, PSMA-based prostate cancer staging, and radiomic modeling for pancreatic adenocarcinoma. His work consistently addresses clinical validation of imaging biomarkers through multi-center trials, emphasizing quantitative analysis for treatment response assessment and nodal metastasis detection. With over 200 publications, Professor Arturo demonstrates sustained leadership in translating advanced imaging techniques—particularly PET/MRI and radioembolization dosimetry—into oncology applications, significantly contributing to protocol standardization in molecular imaging.
Thuy Tran is a Senior Researcher and Associate Professor at the Department of Oncology-Pathology, Karolinska Institutet. She earned her PhD in Biomedical Radiation Science from Uppsala University (2009) and a Master's in Medical Radionuclide Technology from the same institution (2008). Her research focuses on the development of radioactive drugs for cancer diagnostics and therapy, particularly using PET imaging and cyclotron-produced radiometals. Pharmacy Degree, Uppsala University (2005) Master's Degree in Medical Radionuclide Technology, Uppsala University (2008) PhD in Biomedical Radiation Science, Uppsala University (2009) Associate Professor in Experimental Oncology, Lund University (2016) Her work emphasizes Molecular Imaging , Radiopharmaceuticals , and Drug Development for cancer theranostics. She leads the TRANSlational Theranostics group, which explores radiolabeled antibodies, affibody molecules, and novel tracers for tumors with slow kinetics. Thuy Tran's recent publications (2025-2023) highlight advancements in Gallium-68 production, optimized PET tracers like [68Ga]Ga-ABY-025 and [68Ga]Ga-NOTA-PEG2-RM26, and clinical evaluations of radiolabeled compounds for prostate, breast, and brain cancers. Her studies also address automated synthesis methods and pharmacokinetics in preclinical models. The Tran Lab specializes in multi-modality imaging techniques, including PET/CT, SPECT/CT, and MRI, for cancer diagnostics and cell therapy monitoring. Key research areas include Radiopharmaceutical Development Tumor Targeting Radioimmunotherapy Medical Imaging Protocols Theranostic Applications
Christian E. Haarmark Nielsen is a Clinical Associate Professor at the Department of Clinical Medicine, specializing in Clinical Physiology and Nuclear Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences. He is affiliated with Copenhagen University Hospital (Region H) where he conducts clinical research and patient care in nuclear cardiology and related fields, based at Blegdamsvej 3 in Copenhagen. Dr. Haarmark Nielsen's primary research interests focus on advanced cardiac imaging techniques, particularly nuclear cardiology applications. His work spans several key areas: Nuclear cardiology and radionuclide imaging techniques Cardiac amyloidosis diagnosis and management Prostate cancer imaging and bone metastasis detection Electrophysiology and cardiac rhythm disorders Cardio-oncology applications of nuclear imaging Technical advancements in CZT-SPECT imaging systems His recent publication record shows a strong focus on clinical applications of nuclear medicine, with particular emphasis on cardiac imaging and prostate cancer diagnostics. From 2020-2025, he has published extensively on CZT-SPECT technology, cardiac amyloidosis algorithms, and comparative studies of PET/CT imaging for bone metastases. His work bridges technical nuclear medicine advancements with practical clinical applications, appearing in high-impact journals including the Journal of Nuclear Medicine and Journal of Nuclear Cardiology. Dr. Haarmark Nielsen maintains active collaborations across multiple institutions, with research spanning cardiology, oncology, and nuclear medicine specialties. His work on cardiac imaging protocols has gained significant attention, as evidenced by citation metrics including 127 Scopus citations for his 2011 paper on Tpeak-Tend interval prognostic value and Mendeley readership ranging from 6 to 65 across different publications.
